1-3 of 3
David J. Straus
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Lindsey E. Roeker, Tatyana A. Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey, Andrew D. Zelenetz, Lorenzo Falchi, Jae H. Park, David J. Straus, Camila Pena Velasquez, Sonia Lebowitz, Yehudit Fox, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Teja Turpuseema, Michelle Purdom, Dana Paskalis, Hari P. Miskin, Peter Sportelli, Lori A. Leslie, Anthony R. Mato
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 3958–3964.
https://doi.org/10.1158/1078-0432.CCR-22-0964
Published: 15 September 2022
View article titled, Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
Open the PDF for Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach in another window
Includes: Supplementary data
Journal Articles

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero-Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, Gerald Engley, Thomas J. Manley, Keenan Fenton, David J. Straus
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1718–1726.
https://doi.org/10.1158/1078-0432.CCR-18-2435
Published: 15 March 2019
View article titled, Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Open the PDF for Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

Jacob D. Soumerai, Andrew D. Zelenetz, Craig H. Moskowitz, M. Lia Palomba, Paul A. Hamlin, Jr, Ariela Noy, David J. Straus, Alison J. Moskowitz, Anas Younes, Matthew J. Matasar, Steven M. Horwitz, Carol S. Portlock, Jason A. Konner, Mrinal M. Gounder, David M. Hyman, Martin H. Voss, Matthew G. Fury, Devika Gajria, Richard D. Carvajal, Alan L. Ho, Jan H. Beumer, Brian Kiesel, Zhigang Zhang, Alice Chen, Richard F. Little, Christine Jarjies, Thu O. Dang, Fallon France, Nishant Mishra, John F. Gerecitano
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4119–4126.
https://doi.org/10.1158/1078-0432.CCR-16-3068
Published: 01 August 2017
View article titled, The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Open the PDF for The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma in another window
Includes: Supplementary data